Frederick Spaeth, Partner at Dilworth IP, will be presenting at this year’s Joint Patent Practice Seminar at the Marriott Marquis in NYC on May 12th.  Fred will be speaking briefly as part of a panel which will discuss the impact on patent law of recent and various Supreme Court decisions.   His talk is entitled The Nautilus Decision Defines the Test for Indefiniteness: Nautilus v. Biosig Instruments.

For more information and to register for the event, go to

Frederick Spaeth is Partner at Dilworth IP where he chairs the firm’s trademark practice.  He has extensive experience advising clients in the area of intellectual property law, including preparing and prosecuting patent, trademark and copyright applications in the U.S. and abroad, and rendering opinions on validity and infringement.  In addition, he provides counseling in connection with the formation of R&D-based joint ventures, intellectual property licensing, patent landscape studies, clearance/ infringement studies, best practices, intellectual property audits and transaction due diligence and a variety of commercial transactions and agreements including consulting contracts, direct sales and consignment sales, and IT services agreements.  Fred works closely with in-house general counsel and intellectual property managers, and his experience spans a wide range of industries including aerospace, chemistry, electrical and mechanical devices and systems, medical technology and others.  His educational background, which includes study in engineering, a Bachelor of Science degree in Chemistry, a Juris Doctor degree and a Master’s in Business Administration enables him to address a diverse range of legal, technological and business issues.


Dilworth IP is an intellectual property and business law firm providing legal services in the areas of patent and trademark prosecution, opinions, agreements and litigation in the chemical, biotech, pharmaceutical, medical device, material science, consumer products, electronics, software, and semiconductor industries. We’ve been in the lab. Whether your invention is a controlled-release pharmaceutical, a fuel cell, or a new polyolefin catalyst, our attorneys will speak your language and listen well. We’ll quickly grasp nuances of your complex technology and capture the IP protection you deserve. To learn more about the firm, please visit